Arcutis Biotherapeutics Inc

NASDAQ:ARQT   3:59:41 PM EDT
27.26
-2.36 (-7.97%)
Products, Regulatory

Arcutis Completes Enrollment In Late-Stage Trials For ARQ-151 As Potential Treatment For Plaque Psoriasis

Published: 09/16/2020 13:41 GMT
Arcutis Biotherapeutics Inc (ARQT) - Arcutis Completes Enrollment in Dermis-1 and Dermis-2 Pivotal Phase 3 Clinical Trials Evaluating Arq-151 (topical Roflumilast Cream) As a Potential Treatment for Plaque Psoriasis.
Arcutis Biotherapeutics Inc - Phase 3 Trials Topline Data Now Anticipated in Q1 of 2021.
Arcutis Biotherapeutics Inc - New Drug Application (nda) Submission Anticipated by End of 2021.